PureTech Health plc (PTCHF) stock
PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 2/30
$1.48+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
PureTech Health r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $56.57M, down 18.6% from the year before. The highest annual figure on record is $152.43M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $56.57M | -18.6% |
| FY2024 | Dec 31, 2024 | $69.45M | -27.8% |
| FY2023 | Dec 31, 2023 | $96.24M | -36.9% |
| FY2022 | Dec 31, 2022 | $152.43M | +38.0% |
| FY2021 | Dec 31, 2021 | $110.47M | +35.0% |
| FY2020 | Dec 31, 2020 | $81.86M | -4.6% |
| FY2019 | Dec 31, 2019 | $85.85M | +10.9% |
| FY2018 | Dec 31, 2018 | $77.40M | – |
See a number that looks wrong?